

# 行政院國家發展基金管理會新聞稿

---

96.9.14

有關行政院國家發展基金投資宇昌生技股份有限公司乙案，說明如后：

為推動國內生技醫藥產業發展，建立世界級醫藥品研發與製造公司，並與頂尖科學家及國際生技公司合作，行政院國家發展基金經審查決定在2,000萬美元範圍內，以分期撥款方式投資宇昌生技股份有限公司40%股權。本案未來若擬設立生產工廠，國發基金擬在不超過30%股權範圍內進行投資。目前國發基金已投資宇昌生技公司新台幣4,000萬元，並委請中研院翁啟惠院長、何大一博士及陳良博博士代表本基金擔任公司董事、本基金何召集人美玥擔任監察人，以支持該公司進行抗體開發及商業化工作，並促進國內生技產業之進一步發展。

國發基金目前擁有約62億美元資產，積極配合政府政策，致力於參與我國生技產業之創立，並提撥新台幣300億元資金，參與投資我國新設生技公司。截至目前，國發基金共計直接投資於12家我國生技公司及20家國內外生技創業投資事業，投資金額共計約新台幣84億元，期藉由政府資金投入及結合國內外資源，大幅提升我國生技產業競爭力。

宇昌生技公司成功向美國Genentech公司取得授權，

---

# 行政院國家發展基金管理會新聞稿

---

未來將針對治療HIV感染之TNX - 355及其他相關抗體，在台灣進行研發工作，並將產品商業化。TNX - 355在第2a期臨床實驗已展現顯著療效，將於96年第4季在進行第2b期臨床實驗，並規劃於97年第4季進行第3期臨床實驗，未來宇昌生技公司將盡全力以最短之時間完成相關研發作業。宇昌生技公司除引進世界級人才擔任經營研發團隊、與國際級生技公司進行合作外，更擁有堅強之董事會及股東陣容，預期將可為我國生技產業之發展增添相當助力。

。

---

另檢附宇昌生技股份有限公司新聞稿如下：任何有關 Genentech 公司相關問題，敬請逕洽該公司(Genentech 公司新聞對外連絡電話：+1-650-467-6800)

## <Press Release>

TaiMed Biologics, a TaiMed Inc. company, based in Taiwan, announced today that it has in-licensed TNX-355 for the treatment of HIV/AIDS from Genentech, and will commence Phase 2b trials in 4Q 2007.

The proprietary humanized anti-CD4 monoclonal antibody known as TNX-355, for the treatment of HIV, was one of several molecules brought into Genentech upon completion of Genentech's acquisition of Tanox, Inc. on August 7, 2007. Per the company's normal process, all of the molecules in Tanox's pipeline were evaluated to determine the most appropriate path forward for Genentech's portfolio. With the company's three primary research focus areas being oncology, immunology, and tissue growth and repair, the company decided to seek out a collaborator with specific expertise in HIV. Genentech and TaiMed have agreed to enter into an exclusive licensing arrangement which gives TaiMed exclusive rights to develop and commercialize TNX-355 and other anti-CD4 monoclonal antibodies in exchange for undisclosed upfront, milestone and royalty payments.

"Genentech believes that TNX-355 may be a promising therapy in the treatment of HIV. We believe that it is in the best interest of patients to turn this molecule over to TaiMed, a company with the staff and the significant expertise to move quickly in this area," said Susan Desmond-Hellmann, MD, MPH, president, Product Development, Genentech. "Genentech's current pipeline is robust and commands the time and resources of our staff, while TaiMed has secured noteworthy, top-flight HIV research talent, demonstrating its commitment to advance this important molecule as expeditiously as possible. We believe that our collaboration with TaiMed is the best solution for furthering TNX-355's development with the specific goal of bringing a meaningful HIV therapy to patients."

"TaiMed Biologics is delighted to be entrusted by Genentech for the development of TNX-355, a potentially important new drug against HIV/AIDS with a novel mechanism of action. TNX-355 has demonstrated significant efficacy in Phase 2a trials, without significant adverse effects. The company will, proceed to conduct Phase 2b study, in 4Q 2007 with a goal of initiating Phase 3 trials in 4Q 2008 worldwide, including in Taiwan. TaiMed is committed to bringing this novel therapy to patients with HIV infection as rapidly as possible," said David Ho, a scientific founder of and an advisor to TaiMed Biologics as well as the founding scientific director and chief executive officer of the Aaron Diamond AIDS Research Center in New York City, and a professor at Rockefeller University.

"Taiwan government and private sectors are undertaking a massive effort to build biotechnology industry in Taiwan. TaiMed Biologics' collaboration with Genentech represents a major thrust to jump-start this important industry in Taiwan. We shall learn from world's best biotechnology company, Genentech, how to develop this industry in Taiwan within the shortest possible time," commented Ing-wen Tsai, Chairman of TaiMed Inc., and former Vice Premier of the Taiwan government.

"Taiwan government and its people have committed to the long term development of the biotechnology industry. TaiMed-Genentech collaboration signals a new paradigm for developing knowledge-based industry such as biotechnology in the newly industrialized country such as Taiwan. By recruiting world-class talents, like David Ho from the US, persuading a world-class company like Genentech to be a collaborator, and mobilizing resources available in Taiwan, biotechnology industry in its best form is no longer a dream, but a reality, for a country like Taiwan," said Chi-Huey Wong, president of Academia Sinica, a preeminent research institution in Taiwan.

The National Development Fund of Taiwan is a US\$6.2 billion investment fund,

will be an active participant of the Taiwan biotech build-up. We have already ear-marked US\$200M for biotechnology investment. The National Development Fund has already agreed to invest 40% of capital requirements of TaiMed Biologics. At the same time, the government is building two additional biomedical parks to house and foster biotechnology companies, much in the same spirit behind the highly successful Hsinchu Science Park that created Taiwan's vibrant IT industry. One of them, Hsinchu Biomedical Science Park, a 90-acre campus 20 minutes away from Taipei via bullet train, with US\$400M invested already, will open for business in 4Q 2007. TaiMed Biologics will be the first company operated from this exciting, state-of-the-art facility.

TaiMed Inc. is a Taiwan company dedicated to the development of biotechnology industry in Taiwan. In addition to Ing-wen Tsai, David Ho and Chi-Huey Wong, board members include Yuan T. Lee, Nobel Laureate and former president of Academia Sinica; Lan Bo Chen, professor emeritus of Harvard University and founder of Synta Pharmaceuticals in US; and Patrick Y Yang PhD, executive vice president, Product Operations of Genentech. Morris Chang, founder of Taiwan Semiconductor Manufacturing Company (TSMC) heads the business advisory board. The company has, within a short timeframe, broadened its capital base, members of the board, and members of the advisory, as well as fund raising from the private sector. The National Development Fund will be taking part once the private sector fund-raising process is complete.

In addition to TNX-355, TaiMed Biologics is well-underway on the development of second generation monoclonal antibody for the treatment of HIV/AIDS as well as other molecules (e.g., flu vaccines). Taiwan will serve as the main base for these research and development activities. Plans for the launch of phase 3 TNX-355 will also include Taiwan.

TaiMed Biologics is jointly invested by the National Development Fund, Taiwan Global Biofund, President International Development Corp., specializing in biologics such as protein drugs and vaccines. Initial capital is US\$50M. Members of the board include HJ Chang of Taiwan Global BioFund (representing the YFY Group), Ted TC Tu (representing the President International Development Corp), Ing-wen Tsai (representing TaiMed Inc.), CH Wong, David Ho, Lan Bo Chen (representing the National Development Fund) with Minister MY Ho (representing the National Development Fund as supervisor). TaiMed Biologics is pleased to have Patrick Y Yang, PhD, executive vice president, Product Operations of Genentech as an independent board member.

TaiMed Biologics would not have been possible without the full support of the

two key founders to the project, SC Ho, chairman of YFY Group and Nan Tien Chuang, chairman of Prince Housing and Development Corp. Their perseverance and unrelenting support to TaiMed team members is pivotal to the launch of our project. TaiMed Biologics is also indebted to Lan Bo Chen, who has tirelessly led the TaiMed team with his planning, negotiations, and consultations.

Any queries with regards to Genentech should be directed to Genentech's media line: (T) +1-650-467-6800.